BURLINGTON, Mass., July 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States preclinical animal research imaging system market will be significantly driven by the trend toward multimodality imaging, such as combining computed tomography and magnetic resonance imaging with nuclear imaging and optical imaging. This demand stems from the need for higher-quality imaging to satisfy more stringent publication requirements among scientific journals, which will spur preclinical imaging system sales.

Other key findings from Decision Resources Group's coverage of the U.S. preclinical animal research imaging system market:

  • Multimodality imaging: Currently, technical hurdles have precluded the development of integrated PET/MRI systems that allow for simultaneous multimodality imaging; therefore, sequential imaging is done on separate systems, which has driven sales of stand-alone units. However, as integrated systems improve and offer better imaging capabilities, there will be less of a need to purchase separate stand-alone systems.
  • Funding for preclinical research: In recent years, a lack of funding for preclinical research has restricted system sales. However, funding levels are expected to gradually rebound through 2022, which will positively impact the preclinical imaging system market.
  • Vendors working with customers in the grant process: To help facilities obtain funding for their research, preclinical vendors have researchers and grant writers on staff to support the grant process. This strategy can boost companies' brand loyalty among customers and fuel future system purchases.

Comments from Decision Resources Group Analyst Felix Lam:

  • "Although preclinical and clinical imaging technologies are similar, very few players are active in both markets. Producing systems for medical use involves additional regulatory hurdles that can be costly; therefore, most of the smaller preclinical imaging system vendors only compete in the preclinical space."
  • "The lack of overlap between preclinical and clinical vendors will be even more evident given the departure of major players, such as GE Healthcare and Siemens Healthcare, from the preclinical imaging market. This has created significant competitive volatility, with the remaining vendors aggressively competing for newly orphaned customers. Vendors will also need to invest in the marketing gap left by the exit of these large players."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

Decision Resources Group
Christopher Comfort

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

The U.S. Clot Management Device Market Will Experience Accelerating Growth, Reaching Revenues of $700 Million in 2022

View Now